While GGTase-I inhibitors (GGTIs) have received less attention, accumulating evidence suggests GGTIs may augment therapies using FTIs and could be useful to treat a myriad of additional disease states. Here we describe the characterization of a selective, highly potent, and cell-active GGTase-I inhibitor, GGTI-DU40. Kinetic analysis revealed that inhibition by GGTI-DU40 is competitive with the protein substrate and uncompetitive with the isoprenoid substrate; the K i for the inhibition is 0.8 nM. GGTI-DU40 is highly selective for GGTase-I both in vitro and in living cells. Studies indicate GGTI-DU40 blocks prenylation of a number of geranylgeranylated CaaX proteins. Treatment of MDA-MB-231 breast cancer cells with GGTI-DU40 inhibited thrombin-induced cell rounding via a process that involves inhibition of Rho proteins without significantly effecting parallel mobilization of calcium via Gβγ. These studies establish GGTI-DU40 as a prime tool for interrogating biologies associated with protein geranylgeranylation and define a novel structure for this emerging class of experimental therapeutics.
A promising strategy for the development of anti-cancer drugs is to suppress activation of oncogenic proteins such as Ras superfamily members. Functional Ras proteins require the addition of an isoprenoid lipid via a process directed by a C-terminal sequence termed the CaaX motif (1, 2) , in which a cysteine (C) residue is followed by a dipeptide (aa) that is usually aliphatic and a variable residue (X) that dictates the prenyl group added. An X residue of Ser, Met, Gln, Cys, or Ala directs addition of the 15-carbon farnesyl lipid, while a Leu residue can direct modification by the 20-carbon geranylgeranyl isoprenoid (3) .
Following addition of the isoprenoid, most CaaX proteins are further processed by the Rce1 protease, which removes the -aaX residues, and isoprenylcysteine carboxymethyltranferase (Icmt) to yield a protein containing a C-terminal isoprenylcysteine carboxymethylester (4) .
The CaaX prenyltranferases protein farnesyltransferase (FTase) and protein geranylgeranyltransferase type I (GGTase-I) (5) add either a 15 carbon farnesyl group or a 20 carbon geranylgeranyl group, respectively, to the cysteine found within the CaaX motif. The prenyltransferase holoenzyme consists of an alpha subunit that is shared between the two forms of enzymes and a distinct beta subunit that binds substrates and thereby also confers prenyl group specificity (1) . FTase substrates include Ras GTPases, nuclear lamins, several protein kinases and phosphatases, as well as other regulatory proteins (5) . GGTase-I substrates include Rac and 2 Rho GTPases and the gamma subunits of most heterotrimeric G-proteins (6) .
A structural bioinformatics analysis of the human genome has indicated that roughly 130 proteins are modified by the two enzymes, with substrates being divided nearly equally between FTase and GGTase (3) .
The realization that many CaaX proteins, most notably Ras family members, are involved in pathologies such as cancer, inflammation and viral infectivity (4, 7, 8, 9) , has spurred efforts to develop inhibitors of CaaX processing as a rational approach to therapeutic development. The major effort in this regard has been development of FTase inhibitors termed FTIs. FTIs developed rapidly from early CaaX peptide mimics (10) into the small organic ligands that have now shown efficacy in clinical trials, particularly hematologic and breast cancers (11, 12) . FTI development was unusually rapid as multiple groups developed structurally distinct drugs that all demonstrated similar biological/pharmacological properties in preclinical models and unambiguously indicated that drug action was due principally to inhibition of FTase. These results however, have been overshadowed by unexpected clinical shortcomings, particularly against solid tumors (13, 14) . One postulated explanation for this clinical limitation is the increased geranylgeranylation of protein such as K-Ras when FTase activity is inhibited, a processes referred to as alternate prenylation (15, 16, 17) .
The discovery of alternate prenylation, coupled with the increasing evidence for involvement of geranylgeranylated proteins in pathological processes such as cancer, inflammation, and viral infectivity has led to increased interest in therapeutic targeting of GGTase-I. Although development of FTIs has garnered considerably more interest than that of GGTIs, several peptidomimetic GGTIs have been described.
These include aminobenzoic acid derivatives such as GGTI-298 and GGTI-2154 (18, 19) and benzoyleneurea-based compounds (20) . Studies with these compounds have revealed a number of consequences of cellular exposure to a GGTI. Administration of GGTI to cells can cause cell cycle arrest at G 0 /G 1 , and this effect appears to be mediated by inactivation of CDK2/4 through the p21/p15 kinase inhibitors downstream of Rho (21, 22) . GGTIs are also potent stimulators of apoptosis in both normal (23, 24) and transformed cell lines (25, 26) .
The complex nature of CaaX protein localization and function leaves multiple points where disregulation can occur, and therefore multiple points for therapeutic intervention are possible.
Although the efficacy of prenyltransferase inhibitors in treating cancer is now considered quite genuine, if still against a limited number of cancers, the rational application of protein prenyltransferase inhibitors is growing more complex as the roles for multiple GTPases and other CaaX containing proteins are elucidated. To aid in these areas of understanding, we now describe the characterization of a novel pyrozolederived GGTI termed GGTI-DU40. GGTI-DU40 has the encouraging features of being highly selective for GGTase-I, high affinity, and cellactive. These characteristics make GGTI-DU40 desirable as a means to control protein GGTase-I activity and thereby provide a useful tool to assess the biology of geranylgeranylated proteins. GGTI-DU40 is a promising lead compound for therapeutic development targeting pathologies dependent on geranylgeranylated proteins.
Materials and Methods
Materials -Farnesyl diphosphate (FPP) and geranylgeranyl diphosphate (GGPP) were purchased from Biomol, Inc (Plymouth Meeting, PA). S-adenosine-L-methionine (AdoMet) was purchased from Sigma (St. Louis, MO).
3 H-GGPP, 3 H-FPP, and 3 H-AdoMet were purchased from PerkinElmer (Boston, MA). Geneticin was purchased from Invitrogen (Carlsbad, CA). The FTI L-744,832 was purchased from EMD Biosciences (San Diego, CA). StreptavidinSepharose was purchased from Amersham Biosciences (Uppsla Sweden). Biotin-S-farnsyl-L-cysteine was synthesized and purified as previously described (27) . GGTI-DU40 and its inactive analog, SN-DU40, were synthesized by PPD Discovery (Research Triangle Park, NC) and by the Duke Small Molecule Synthesis Facility; the preparation of these compounds will be described elsewhere.
Enzyme Assays -FTase and GGTase-I activities were determined by following incorporation of radiolabeled isoprenoid from 3 H-FPP and 3 H-GGPP into Ras proteins as described previously (28). Briefly, purified mammalian FTase or GGTase-I (50 ng, expressed in Sf9 cells) (29, 30) were used to initiate reactions containing 0.5 µM FPP or GGPP, respectively and 1 µM of the appropriate purified His-tagged Ras substrates (H-Ras for FTase; Ras-CVLL for GGTase-I). Where indicated in the appropriate Figure legend, inhibitors were added at the indicated concentrations. Final DMSO concentration was 2% for all samples. Reactions were carried out for 10 min at 30 o C before precipitation and product determination. Kinetic assays in which GGPP concentration was varied employed 5 ng GGTase-I, and reactions were carried out for five min to prevent GGTase-I concentration from exceeding GGPP concentration.
GGTase-II activity was measured used bovine brain cytosol (200 µg protein) as the enzyme source and purified GST-tagged Rab5a as the protein substrate. The pGEX-Rab5a construct was a gift from Adrienne Cox (University of North Carolina). The assay was performed identically to that described above for the CaaX prenyltransferases except for the enzyme source and protein substrate and that the reaction time was increased to for 30 min.
Icmt assays were performed as described previously (27) . Briefly, reactions were performed using biotin-S-farnsyl-L-cysteine (4 µM) as a substrate and 3 H-AdoMet (5 µM, 7.5 Ci/mmol) as a methyl donor. Reactions were initiated by the addition of Sf9 membranes containing recombinant human Icmt (2 µg totoal protein) in the presence and absence of inhibitors. Reactions were carried out at room temperature for 20 min, and product formation determined.
Cell Culture and Microscopy -MDCK cells stably expressing GFP-H-Ras were a gift from Mark Philips (New York University School of Medicine). Ras-CVLL was cloned into pEGFP (Clontech) and used to transfect MDCK cells. Stable clones were then selected using both Geneticin and expression confirmed by analysis of GFP expression as visualized by fluorescence microscopy. MDCK cells were always cultured as a monolayer in DMEM with 10% FBS. For drug treatment experiments, cells were plated onto glass-bottom microwell dishes (MatTek Corp, Ashland, MA) and experiments initiated approximately 24 h after cells reached confluence. All compounds tested were dissolved in DMSO and added to cells at a final DMSO concentration of 0.02%.
For the experiments assessing thrombin effects on cell morphology, MDA-MB-231 cells were plated onto glass-bottom microwell dishes at 10-20% confluence and grown for 18-24 h in the presence of serum. Cells were then washed once with PBS and media replaced with serum-free media (DMEM) including indicated compounds and incubated an additional 24 h. Cells were then imaged, treated with thrombin (1 U/mL for 20 min), and imaged again.
Assessment of receptor independent cell rounding was accomplished using adenovirus expressing the activated mutant of Gα12, Gα12 QL (31) . MDA-MB-231 cells were plated onto glassbottom microwell dishes at 60% confluence and grown for 18-24 h in the presence of serum. Cells were then washed once with PBS and media replaced with serum-free media (DMEM) including any indicated compounds and incubated 6 h before addition of recombinant adenovirus. Following an additional 12 h incubation, cells were imaged using brightfield and GFP fluorescence microscopy. Cell images were acquired using an Eclipse TE300 microscope (Nikon) using either an oil immersion lens at 600x (for fluorescence of MDCK cells) or a plan fluor lens at 200x (for MBA-321 cells) and a SPOT digital camera (Diagnostic Instruments, Sterling Heights, MI) employing SPOT RT 3.02 software.
Calcium Mobilization Studies -For the experiments assessing thrombin-induced calcium flux, MDA-MB-231 were plated on glass coverslips and treated similarly to that described for the thrombin rounding experiments. Calcium flux was measured 24 h after withdrawal of serum and addition of inhibitors using the calciumsensitive dye Fura 2-AM (Molecular Probes Inc) (32) . MDA-MB-231 cells were dye loaded for 1 h with 2.5 µM Fura-2 AM in Hanks balanced salt solution (HBSS, supplemented with 10 mM glucose and 0.1% BSA). After dye loading, the coverslips were placed in a temperature controlled recording chamber and superfused with Hanks solution. Cells were excited alternately at 340 and 380 nm and fluorescence emission at 510 nm was measured every four sec during the course of each experiment. After baseline recording for 2 min, thrombin (1 U/mL) was superfused into the bath chamber for 1 min (~20 mL), followed by washout.
Data is presented after baseline subtraction to show thrombin dependent calcium flux. Fluorescence measurements were acquired using a DeltaScan Illumination System (Photon Technology International (PTI), South Brunswick, NJ) running on FELIX 1.4 software.
Gβγ membrane partitioning -MDA-MB-231 cells were grown in 10 cm dishes and treated exactly as in the thrombin cell rounding assay. Following drug treatment in serum free media, cells were harvested and lysed using ice cold hypotonic lysis buffer (70 mM HEPES pH 7.4, 2 mM EDTA, 1mM DTT, and protease inhibitors). Following sonication, the whole cell lysate (75 µg protein) was centrifuged at 100,000 x g for 45 min. Both the supernatant (S100) and pellet (P100) fractions were processed on 4-20% SDSpolyacrylamide gels and proteins transferred to nitrocellulose membranes for immunoblot analysis.
RhoGDI-Rho interaction assay -The interaction of GST-RhoGDI with endogenous Rho was assessed by protein interaction experiments. RhoGDI was generated as a glutathione-Stransferase fusion protein using a construct provided by Gary Bokoch (Scripps). The GSTRhoGDI fusion protein was incubated with treated MDA-MB-231 cell lysates (prepared identically to Gβγ partitioning above) for 1 hr at 4 o C in a total volume of 200 µl. Glutathione-sepharose was added and the mixture rotated at 4 o C for 30 min after which the affinity matrix was pelleted and washed three times with 500 µl of incubation buffer (70 mM HEPES, pH 7.5, 2 mM EDTA, 1 mM DTT, 150 mM NaCl, 0.1% Tween, 100 µM GDP, 2 mM MgCl 2 ). Proteins retained on the matrix were solubilized in 2x Laemmli loading buffer and separated by electrophoresis on denaturing, 4-20% polyacrylamide gels. Proteins were transferred to nitrocellulose membranes for immunoblotting with an anti-RhoA antibody (Santa Cruz, sc-179).
Unprenylated Rap1 analysis -To measure levels of unprenylated Rap1 in cells, whole cell lysates of MDA-MB-231 cells (prepared identically to Gβγ partitioning above, 75 ug) were mixed with Laemmli loading buffer and boiled. Samples were then separated by electrophoresis on denaturing 4-20% polyacrylamide gels and proteins transferred to nitrocellulose membranes for immunoblotting with antisera specific for the unprenylated form of Rap1 (Santa Cruz, sc-1482, goat). Sample loading was verified by reprobing blots with antisera for total Rap1 (Santa Cruz, sc-65, rabbit).
Miscellaneous Methods -Graphing and curve fitting were performed using Prism (GraphPad, SanDiego CA). Substrate-velocity curves were fit to the Michaelis-Menten equation, while double-reciprocal plots were fit using linear regression.
The K i for GGTI-DU40 was calculated using nonlinear regression and shared parameter curve fitting for all inhibitor concentrations, the velocity equation used was v =
Results

Identification of GGTI-DU40, a potent inhibitor of GGTase-I
A diverse chemical library was screened for GGTase-I inhibitors using an in vitro assay, and a novel pyrazole-based inhibitor with an IC 50 of ~10 µM was discovered. Medicinal chemists at PPD Discovery (Research Triangle Park, NC) then optimized this structure for potency. The result of this optimization was a novel compound which we have dubbed GGTI-DU40 (Fig. 1A, N- 
The medicinal chemistry route to the refinement of this compound will be reported separately (J.P. Strachen et al, in preparation).
Kinetic analysis of GGTase-I inhibition by GGTI-DU40
In an initial examination of the selectivity of GGTI-DU40, the ability of the compound to inhibit GGTase-I and other enzymes in the prenylation pathway was determined (Fig. 1B) . GGTI-DU40 was a highly potent inhibitor of purified GGTase-I exhibiting an IC 50 of 8.24+/-0.97 nM. GGTI-DU40 inhibition of FTase was barely detectable in the concentration range tested, exhibiting an IC 50 for this closely-related enzyme of >2 µM, corresponding to a FTase/GGTase-I selectivity ratio of >250. GGTI-DU40 showed no detectable activity against GGTase-II (Rab geranylgeranyltransferase) nor against Icmt methyltransferase (Fig. 1B) . These data indicate GGTI-DU40 is a highly potent and selective inhibitor of GGTase-I. A structural analogue of GGTI-DU40, SN-DU40, that contains a single sulfur-to-nitrogen substitution (Fig. 1A) , was also tested for GGTase-I inhibition.
This single substitution resulted in a compound with an IC 50 of >2 µM for GGTase-I, providing a useful control for confirming mechanism-based effects of GGTI-DU40 in cells (see below).
GGTI-DU40 is of a distinct structural class than all other reported protein prenyltransferase inhibitors.
Hence, it was considered important to understand the mechanism of GGTase-I inhibition by the compound. Accordingly, we undertook Michaelis-Mententype analysis of the inhibition of GGTase-I. These kinetic data revealed that GGTI-DU40 is a competitive inhibitor with respect to the protein substrate (Fig. 2, panels A,C) , and an uncompetitive inhibitor with respect to GGPP (Fig  2, panels B,D) . Hence, GGTI-DU40 competes for binding of the protein substrate, but not the isoprenoid substrate of GGTase-I. This feature likely contributes to this compound's high selectivity for GGTase-I. Analysis of the protein substrate competition data confirmed the high affinity of GGTI-DU40; the resultant calculated K i was of 0.78+/-0.10 nM. Given this high affinity, we tested GGTI-DU40 for potential timedependent inhibition of GGTase-I, but no such behavior was observed (data not shown). These data establish GGTI-DU40 as a novel high affinity structure targeting the CaaX binding site of a protein prenyltransferase.
Cellular Activity of GGTI-DU40
Since GGTI-DU40 demonstrated favorable properties as a GGTase-I inhibitor in vitro, we explored its utility in targeting this enzyme in cells. An amenable system to evaluate the cellular effects of protein prenyltransferase inhibitors utilizes subcellular distribution of fluorescently-tagged fusions of Ras proteins. Wild type H-Ras normally localizes to the plasma membrane due to its ability to be modified by FTase, followed by processing by Rce1 and Icmt, at its C-terminal sequence: CVLS. A variant of HRas, Ras-CVLL, contains a CaaX sequence terminating in Leu and thus its processing is initiated by geranylgeranylation by GGTase-I. In stably-transfected MDCK cells treated with either the vehicle DMSO (data not shown) or the inactive GGTI-DU40 analogue SN-DU40, both H-Ras and Ras-CVLL are predominantly localized to the plasma membrane (Fig. 3, panels A,B) . Treatment with the FTI inhibitor L-744,832 (33) resulted in almost complete mislocalization of H-Ras (Fig.  3C ), but no detectable mislocalization of Ras-CVLL was observed even at the highest concentration tested (20 µM, Fig. 3D ) indicating the Ras-CVLL construct is exclusively geranylgeranylated in cells. On the other hand, treatment with GGTI-DU40 resulted in complete mislocalization of Ras-CVLL such that plasma membrane localized Ras was barely detectable (Fig. 3F) , while this compound was without an effect on localization of H-Ras (Fig. 3E) . Ras-CVLL mislocalization by GGTI-DU40 treatment could be detected at inhibitor concentrations as low as 2 µM (data not shown).
Consequences of GGTI-DU40 Treatment on Cell Signaling
To further evaluate the effects of GGTase-I inhibition in cells, we chose the MDA-MB-231 adenocarcinoma cell line because its established biology (34, 35, 36) . In initial studies, the ability of GGTI-DU40 treatment to impact the prenylation of a known geranylgeranylated protein was assessed using an antibody specific for the unprenylated form of Rap1. Upon GGTI-DU40 treatment of the MD-MBA-231 cells, a dose dependent increase in the level of unmodified Rap1 was observed (Fig. 4A) . As expected, administration of FTI L-744,832 had no effect on Rap1 prenylation status. These data indicated the capacity of GGTI-DU40 to inhibit prenylation of endogenous proteins.
We next addressed whether GGTI administration could block normal functions of prenylated proteins. An attractive model here involves Rho GTPases. A major class of proteins that directly associate with Rho proteins in cells are termed RhoGDIs, and their binding to Rho GTPases is via an interaction that is known to be prenylation-dependent (37) . Hence, we assessed the ability of GGTI-DU40 treatment of cells to impact on the ability of endogenous Rho proteins to bind RhoGDI. This interaction was directly measured in MDA-MB-231 cells using a GSTRhoGDI pull-down approach to assess the relative amount of endogenous Rho that was able to interact with RhoGDI after inhibitor treatment. As seen in Fig. 4B, a 24 h treatment of the cells GGTI-DU40 led to an almost complete loss in the ability of Rho proteins to associate with RhoGDI; this is precisely what would be expected if geranylgeranylation of Rho was blocked. In contrast, treatment of the cells with the FTI had no effect on the ability of Rho to interact with RhoGDI (Fig. 4B) .
Signaling through the thrombin receptor in MDA-MB-231 cells results in a cell rounding phenotype that is principally mediated via the Rho GTPase (38, 35) . In MDA-MB-231 cells treated with either the inactive analog SN-DU40 or the FTI, normal rounding in response to thrombin treatment was observed (Fig. 5) .
However, treatment of these cells with GGTI-DU40 dramatically inhibited thrombin-stimulated cell rounding (Fig 5) .
Although GGTase-I inhibition clearly impacted Rho function at the level of RhoGDI interaction (Fig. 4) and also Rho-mediated biology (thrombin-induced cell rounding; Fig. 5 ), there is clearly one other family of GGTase-I substrates that could have been important in the latter result. Specifically, Gγ subunits from heterotrimeric Gproteins are prenylated, and the majority are geranylgeranylated (39) . To test the potential impact of GGTI-DU40 on Gγ subunits, membrane partitioning of Gβγ and calcium mobilization, the latter a downstream biology of thrombin receptor activation that is not dependent on Rho proteins, were determined in cells treated with GGTI-DU40. While GGTI treatment did elicit a partial loss of membrane-associated Gβγ (Fig. 6, upper  panel) , indicating a partial inhibition of Gγ prenylation, the majority of the Gβγ remained membrane-associated following this treatment. Furthermore, the ability of thrombin to elicit calcium mobilization following this GGTI treatment was unaffected (Fig. 6, lower panel) , even though the same treatment conditions blocked thrombin's ability to stimulate cell rounding (Fig. 5) . These data indicated that G protein coupling of the thrombin receptor is essentially unaffected by a 24 hr treatment of cells with the GGTI, and further point to an impact on Rho as being responsible for the cell rounding phenotype. In further support of this assessment, rounding of MDA-MB-231 cells elicited by expression of dominant-activate Gα12 (Gα12 QL ), which directly engages the Rho axis without receptor involvement, was also blocked by GGTI-DU40 (Supplemental Fig. 1 ). Taken together, these data demonstrate a clear impact on function and signaling of Rho proteins by GGTase-I inhibition, and also indicate that it is possible to achieve a level of selectivity in inhibiting function of specific geranylgeranylated proteins in cells.
Discussion
The data presented herein detail the properties of a new class of GGTase-I inhibitor. GGTI-DU40 is a potent inhibitor of GGTase-I with K i of <1 nM. Inhibition of GGTase-I by the compound was competitive with the protein substrate, which likely accounts for its high degree of specificity.
GGTI-DU40 is a cell-active compound, as demonstrated by its ability to elicit mislocalization of a geranylgeranylated form of HRas expressed in cells and its ability to attenuate Rho-dependent rounding of MBA-231 cells. As such, GGTI-DU40 provides a novel inhibitor that will facilitate rational manipulation of GGTase-I mediated biologies and signaling processes in mammalian cells.
Mechanistically GGTI-DU40 competes for the CaaX peptide binding site on GGTase-I. In this property it is similar to several other described GGTIs, although structurally GGTI-DU40 is distinct from other inhibitors of the enzyme. The most obvious difference between GGTI-DU40 and the best-detailed GGTIs is that the latter are peptidomimetics and thus retain many features of the CaaX peptides (18) (19) 40) .
The newest optimizations of these peptidomimetic inhibitors focused on removing the thiol contained within the cysteine residue mimic, leading to the generation of imidazole and pyridine substituted compounds (19) . GGTI-DU40 has a similarity to these newer compounds due to its pyrazole located in a position similar to the imidazole found, for example, in GGTI-2147 (19) . However, GGTI-DU40 has a nearly fully substituted pyrazole group (methylsulfanyl-ethyl, dichlorobenzene, and a pyridine), whereas other GGTIs do not. These structural features hint at multiple interaction sites that participate in the high affinity interaction between GGTI-DU40 and GGTase-I.
One unexpected finding of our study was the preferential blockade of monomeric G protein signaling, via an impact on Rho, verus heterotrimeric G protein signaling, via an impact on Gβγ.
One potential mechanism for the selective effects is the variable half-life/stabilities of different geranylgeranylated proteins. Further investigation of this property is warranted since selective blockade of specific geranylgeranylated proteins and signaling pathways could expand the utility of GGTase-I inhibitors as biological tools and in therapeutic applications.
The important role for geranylgeranlyated proteins such as Rho, in numerous diseases is increasingly being appreciated (41, 42, 36) . In addition to potentially suppressing alternate prenylation of K-Ras, the impact of GGTI-DU40 on proteins such as RhoA/C and Cdc42 may prove to be beneficial in limiting oncogenesis by inhibiting proliferation and invasion (43, 44, 36) . Rho activity has a clear function in angiogenesis (45) , which in turn plays a critical role in the pathogenesis of tumors, rheumatoid arthritis, atherosclerosis, psoriasis, and diabetic retinopathy (46) .
In multiple sclerosis, leukocytes and monocytes infiltrate into the central nervous system as part of an inappropriate inflammatory response, and recent evidence suggests that this migration requires Rho signaling and that inhibition of prenylation can lead to decreased inflammatory disease progression (47, 48) . Additionally, replication of Hepatitis C virus can be attenuated by inhibiting GGTase-I, providing a new therapeutic prospect for this increasinglyprevalent disease (49, 50) . Further experiments using GGTIs alone and in combination with FTIs and other first-line anti-cancer agents are necessary to evaluate the impact these agents could have on specific cancers and other pathologies; such studies will determine the appropriateness of where and when GGTIs should enter clinical trials.
There is now a clear relationship between mechanism-based inhibition of CaaX motif processing and attenuation of tumor progression and other pathologies, and effective GGTIs will be indispensable in elucidating these processes while also providing the tools to test the hypothesis that inhibition of this enzyme could have therapeutic benefits. GGTI-DU40 treatment inhibits Rap1 geranylgeranylation. Whole cell lysates from cells treated with GGTI-DU40 or vehicle for 24 h were harvested and processed for immunoblot analysis using an antisera specific for the unprenylated form of Rap1a (upper panel). The blot was then stripped and reprobed with an antisera recognizing total Rap1 (lower panel). The immunoblots presented are representative of four independent experiments for each condition. B. GGTI-DU40 treatment blocks Rho association with RhoGDI. Whole cell lysates from cells treated with GGTI-DU40 (5 µM), FTI L-744,832 (20 µM) or vehicle as in panel A were incubated with GSTRhoGDI or GST alone, following which bound proteins were isolated using glutathione sepharose. Samples, including the input cell lysates (representing 50% of that used in the pulldown) were then processed for immunoblot analysis using Rho-specific antisera. The immunoblot presented is representative of more than four independent experiments. by guest on October 30, 2017 
